CUE (Cue Biopharma, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CUE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Pamela Garzone | Director | A | — | — |
| 2026-08-28 | Pasha Sarraf | Director | A | — | — |
| 2026-08-17 | Michael Vincent Meluzio | VP, Prin. Accounting Officer | MIXED | — | — |
| 2026-08-17 | Sumita Ray | Chief Legal Compliance Officer | MIXED | — | — |
| 2026-08-14 | Shao-Lee Lin | Chief Executive Officer | MIXED | — | — |
| 2026-08-03 | James M Ahlers | Chief Financial Officer | A | — | — |
| 2026-07-30 | Shao-Lee Lin | Chief Executive Officer | A | — | — |
| 2026-07-15 | Dominique Christian Borie | Chief Medical Officer | A | — | — |
| 2026-07-10 | Pamela Garzone | Director | A | — | — |
| 2026-07-10 | Daniel A. Camardo | Director | A | — | — |
| 2026-07-10 | Sumita Ray | Chief Legal Compliance Officer | A | — | — |
| 2026-07-10 | Shao-Lee Lin | Chief Executive Officer | A | — | — |
| 2026-07-10 | Pasha Sarraf | Director | A | — | — |
| 2026-07-10 | Michael Vincent Meluzio | VP, Prin. Accounting Officer | A | — | — |
| 2026-07-10 | Viola Mong Meehan | Director | A | — | — |
| 2026-06-08 | Daniel A. Camardo | Director | A | — | — |
| 2026-06-03 | Shao-Lee Lin | Chief Executive Officer | Buy | — | — |
| 2026-06-02 | Viola Mong Meehan | Director | A | — | — |
| 2026-05-07 | Shao-Lee Lin | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-04-10 | Lucinda Warren | CHIEF BUSINESS OFFICER | A | — | — |
| 2026-04-10 | Colin Sandercock | SVP, GENERAL COUNSEL | A | — | — |
| 2026-04-10 | Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | A | — | — |
| 2026-01-06 | Patrick Verheyen | Director | A | — | — |
| 2026-01-06 | Pamela Garzone | Director | A | — | — |
| 2026-01-06 | Frank Morich | Director | A | — | — |
| 2026-01-06 | Jill Marie Broadfoot | Director | A | — | — |
| 2026-01-06 | Pasha Sarraf | Director | A | — | — |
| 2026-01-06 | Peter A Kiener | Director | A | — | — |
| 2026-01-02 | Pasha Sarraf | Director | Buy | — | — |
| 2025-12-05 | Colin Sandercock | SVP, GENERAL COUNSEL | A | — | — |
| 2025-11-25 | Lucinda Warren | CHIEF BUSINESS OFFICER | A | — | — |
| 2025-11-25 | Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | A | — | — |
| 2025-10-02 | Usman Azam | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-06-06 | Jill Marie Broadfoot | Director | A | — | — |
| 2025-03-25 | DANIEL R PASSERI | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-03-25 | Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-03-25 | Colin Sandercock | SVP, GENERAL COUNSEL | A | — | — |
| 2025-03-25 | Matteo Levisetti | Chief Medical Officer | A | — | — |
| 2025-03-25 | Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | A | — | — |
| 2025-03-25 | Lucinda Warren | CHIEF BUSINESS OFFICER | A | — | — |
| 2025-03-12 | Pasha Sarraf | Director | A | — | — |
| 2025-01-03 | FREDERICK W DRISCOLL | Director | A | — | — |
| 2025-01-03 | Frank Morich | Director | A | — | — |
| 2025-01-03 | Peter A Kiener | Director | A | — | — |
| 2025-01-03 | Patrick Verheyen | Director | A | — | — |
| 2025-01-03 | Pamela Garzone | Director | A | — | — |
| 2024-12-18 | DANIEL R PASSERI | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2024-11-29 | Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | A | — | — |
| 2024-09-05 | Lucinda Warren | CHIEF BUSINESS OFFICER | A | — | — |
| 2024-06-07 | Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 716,455 | — |
| — | Chief Legal Compliance Officer | 124,991 | — |
| — | VP, Prin. Accounting Officer | 53,070 | — |
| — | Director | 36,833 | — |
| — | Chief Medical Officer | 31,500 | — |
| — | Director | 29,195 | — |
| — | Director | 25,617 | — |
| — | Chief Financial Officer | 25,500 | — |
| — | Director | 24,620 | — |
| — | Director | 21,800 | — |
| — | Director | 21,800 | — |
| — | Director | 18,900 | — |
| — | CHIEF EXECUTIVE OFFICER | 5,486 | — |
| — | PRESIDENT AND CSO | 4,521 | — |
| — | Director | 1,000 | — |
| — | Director | 933 | — |
| — | CHIEF FINANCIAL OFFICER | 571 | — |
| — | SVP, GENERAL COUNSEL | 571 | — |
| — | Chief Medical Officer | 500 | — |
| — | Director | 323 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CUE quote page; the site-wide leaderboard is on the insider transactions hub.